JP2009526770A - 転移性乳癌の治療 - Google Patents

転移性乳癌の治療 Download PDF

Info

Publication number
JP2009526770A
JP2009526770A JP2008553685A JP2008553685A JP2009526770A JP 2009526770 A JP2009526770 A JP 2009526770A JP 2008553685 A JP2008553685 A JP 2008553685A JP 2008553685 A JP2008553685 A JP 2008553685A JP 2009526770 A JP2009526770 A JP 2009526770A
Authority
JP
Japan
Prior art keywords
epcam
treatment
dose
patients
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008553685A
Other languages
English (en)
Japanese (ja)
Inventor
カーステン ラインハート
ロバート サラー
Original Assignee
マイクロメット アクツィエン ゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マイクロメット アクツィエン ゲゼルシャフト filed Critical マイクロメット アクツィエン ゲゼルシャフト
Publication of JP2009526770A publication Critical patent/JP2009526770A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2008553685A 2006-02-09 2007-02-09 転移性乳癌の治療 Pending JP2009526770A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77242106P 2006-02-09 2006-02-09
EP06002680 2006-02-09
PCT/EP2007/001127 WO2007090670A1 (en) 2006-02-09 2007-02-09 Treatment of metastatic breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012272352A Division JP2013067645A (ja) 2006-02-09 2012-12-13 転移性乳癌の治療

Publications (1)

Publication Number Publication Date
JP2009526770A true JP2009526770A (ja) 2009-07-23

Family

ID=38110762

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008553685A Pending JP2009526770A (ja) 2006-02-09 2007-02-09 転移性乳癌の治療
JP2012272352A Pending JP2013067645A (ja) 2006-02-09 2012-12-13 転移性乳癌の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012272352A Pending JP2013067645A (ja) 2006-02-09 2012-12-13 転移性乳癌の治療

Country Status (9)

Country Link
US (3) US7976842B2 (https=)
EP (1) EP1981539B1 (https=)
JP (2) JP2009526770A (https=)
KR (1) KR101296264B1 (https=)
AU (1) AU2007213920B2 (https=)
CA (1) CA2638040A1 (https=)
IL (1) IL192944A0 (https=)
RU (1) RU2434640C2 (https=)
WO (1) WO2007090670A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013067645A (ja) * 2006-02-09 2013-04-18 Amgen Research (Munich) Gmbh 転移性乳癌の治療
JP2024073594A (ja) * 2011-05-16 2024-05-29 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
US12577305B2 (en) 2018-12-24 2026-03-17 Itabmed (Hk) Limited Multispecific antigen binding proteins capable of binding CD19 and CD3, and use thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
DE102006035617A1 (de) * 2006-07-31 2008-02-21 Siemens Ag Automatische Bestimmung von Tumorlast
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EA026578B1 (ru) * 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
JP5130999B2 (ja) * 2008-03-31 2013-01-30 住友ベークライト株式会社 抗癌剤の有効性予測方法
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
FR2977674B1 (fr) * 2011-07-06 2015-08-14 Cisbio Bioassays Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US20130179184A1 (en) * 2012-01-06 2013-07-11 Katherine L. Hurst Individualized Dosing Technique With Multiple Variables
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015065505A1 (en) * 2013-10-29 2015-05-07 Duke University Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
US10975164B2 (en) 2018-02-26 2021-04-13 Emory University Antibodies useful for detection of human carcinoma antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
WO2005080428A2 (en) * 2004-02-13 2005-09-01 Micromet Ag Anti-epcam immunoglobulins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
RU2188025C2 (ru) * 2000-07-19 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака молочной железы
AU2007213920B2 (en) * 2006-02-09 2013-08-29 Amgen Research (Munich) Gmbh Treatment of metastatic breast cancer
RU2769948C2 (ru) * 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
WO2005080428A2 (en) * 2004-02-13 2005-09-01 Micromet Ag Anti-epcam immunoglobulins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5008024647; ＰＲＡＮＧ，　Ｎ．，　ｅｔ　ａｌ．: 'Ｃｅｌｌｕｌａｒ　ａｎｄ　ｃｏｍｐｌｅｍｅｎｔ-ｄｅｐｅｎｄｅｎｔ　ｃｙｔｏｔｏｘｉｃｉｔｙ　ｏｆ　Ｅｐ-ＣＡＭ-ｓｐｅｃｉｆｉｃ　ｍｏｎｏｃｌｏｎａｌ　ａｎｔｉｂｏｄｙ　ＭＴ２０１　ａｇａｉｎｓｔ' ＢＲＩＴＩＳＨ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＡＮＣＥＲ Ｖｏｌ．９２，　Ｎｏ．２, 20050131, ｐ．３４２-３４９ *
JPN5008024648; ＲＡＵＭ，　Ｔ．，　ｅｔ　ａｌ．: 'Ａｎｔｉ-ｓｅｌｆ　ａｎｔｉｂｏｄｉｅｓ　ｓｅｌｅｃｔｅｄ　ｆｒｏｍ　ａ　ｈｕｍａｎ　ＩｇＤ　ｈｅａｖｙ　ｃｈａｉｎ　ｒｅｐｅｒｔｏｉｒｅ：　ａ　ｎｏｖｅｌ　ａｐｐｒｏａｃｈ　ｔｏ　ｇｅｎｅｒａｔｅ' ＣＡＮＣＥＲ　ＩＭＭＵＮＯＬＯＧＹ　ＡＮＤ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖｏｌ．５０，　Ｎｏ．３, 200105, ｐ．１４１-１５０ *
JPN5008024649; ＮＡＵＮＤＯＲＦ，　Ｓ．，　ｅｔ　ａｌ．: 'ＩＮ　ＶＩＴＲＯ　ＡＮＤ　ＩＮ　ＶＩＶＯ　ＡＣＴＩＶＩＴＹ　ＯＦ　ＭＴ２０１，　Ａ　ＦＵＬＬＹ　ＨＵＭＡＮ　ＭＯＮＯＣＬＯＮＡＬ　ＡＮＴＩＢＯＤＹ　ＦＯＲ　ＰＡＮＣＡＲＣＩＮＯＭＡ　ＴＲＥＡＴＭＥＮＴ' ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＡＮＣＥＲ Ｖｏｌ．１００，　Ｎｏ．１, 2002, ｐ．１０１-１１０ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013067645A (ja) * 2006-02-09 2013-04-18 Amgen Research (Munich) Gmbh 転移性乳癌の治療
JP2024073594A (ja) * 2011-05-16 2024-05-29 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
US12577305B2 (en) 2018-12-24 2026-03-17 Itabmed (Hk) Limited Multispecific antigen binding proteins capable of binding CD19 and CD3, and use thereof

Also Published As

Publication number Publication date
KR101296264B1 (ko) 2013-08-14
RU2008130963A (ru) 2010-03-20
EP1981539A1 (en) 2008-10-22
CA2638040A1 (en) 2007-08-16
IL192944A0 (en) 2009-02-11
WO2007090670A1 (en) 2007-08-16
US20090304716A1 (en) 2009-12-10
US8658172B2 (en) 2014-02-25
US20130177578A1 (en) 2013-07-11
US8337843B2 (en) 2012-12-25
EP1981539B1 (en) 2014-07-23
AU2007213920A1 (en) 2007-08-16
US20120009204A1 (en) 2012-01-12
KR20080091817A (ko) 2008-10-14
US7976842B2 (en) 2011-07-12
JP2013067645A (ja) 2013-04-18
RU2434640C2 (ru) 2011-11-27
AU2007213920B2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
JP2009526770A (ja) 転移性乳癌の治療
US20240360235A1 (en) Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
US20220288199A1 (en) Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers
Pérez-García et al. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
JP6695003B2 (ja) 癌のための併用療法
US20180134803A1 (en) Treatment of her2-positive breast cancer
JP2024502243A (ja) 無細胞ｄｎａ断片化を用いた肺癌の検出
CN112912403A (zh) 治疗肿瘤的方法
Higashi et al. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer
TW202043273A (zh) 用於晚期實性瘤癌症之治療性ｒｎａ
Hashimoto et al. Metabolic tumor volume as significant predictor for chemotherapy containing PD-L1 blocker in extensive stage small cell lung cancer
KR102265159B1 (ko) 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도
WO2014028221A1 (en) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
HK1123987A (en) Treatment of metastatic breast cancer
HK1123987B (en) Treatment of metastatic breast cancer
TW202529802A (zh) 胃癌和／或胃食管結合部癌的治療
Wirth et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma
Sparano et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in human immunodeficiency virus-associated, B-cell non-Hodgkin lymphoma
WO2026055614A1 (en) Combination of zimberelimab and domvanalimab
WO2023147673A1 (en) Combination therapy for use in treatment of non-small cell lung cancer
Cruz-Merino et al. Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study
CN118900700A (zh) 用于治疗非小细胞肺癌的联合疗法
JP2026513770A (ja) 抗ｃｔｌａ４抗体を使用して黒色腫を治療する方法
JP2026514016A (ja) 非小細胞肺癌の治療
KN026 et al. A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of KN026 in Combination with Chemotherapy in Subjects with HER2-positive Gastric Cancer (including Adenocarcinoma of Esophagogastric Junction) Who Have Failed First-line Treatment

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120813

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20120921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130327

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130402

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130426